

Press release

Ian Kimber joins the board of SenzaGen AB

2015-04-15, Lund, Sweden

SenzaGen AB, a diagnostic spin-off company from Lund University, is proud to announce that Prof. Ian Kimber will join the Board of Directors.

SenzaGen AB is a diagnostic company working to replace animal testing for sensitization predictions.

Prof Ian Kimber is currently Professor of Toxicology and Associate Dean for Business Development in the Faculty of Life Sciences at the University of Manchester. He has broad research interests at the interface between toxicology and immunology, with a particular focus on allergy and inflammation. Professor Kimber holds, and has held, a variety of positions on national and international expert and scientific advisory committees. Currently these include the following: Member UK Medicines and Healthcare products Regulatory Agency (MHRA) Committee for Safety of Devices, Programme Advisor Food Standards Agency Food Allergy and Intolerance Research Programme, and member MRC Translational Research Group. Professor Kimber was previously President of the British Toxicology Society (BTS) (2012-2014), and Chairman of the Board of the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs) (2008-2013).

“I am delighted to be joining the Board of SenzaGen at such an exciting period of growth. Since our initial studies that led to the development and ultimate validation of the Local Lymph Node Assay I have maintained a keen interest in chemical allergy and in the development of novel approaches for improved hazard identification and risk assessment. In this respect harnessing fully the opportunities afforded by developments in the biomedical sciences is critical, and the work of SenzaGen in exploiting a genomic approach to pathway analysis and risk assessment is at the cutting edge of new developments”, says Prof Kimber.

Ian Kimber has published over 600 research papers, review articles and book chapters, and serves currently on the editorial boards of toxicology, immunology, dermatology and pathology journals.

“We are very happy to have Prof Kimber on board in SenzaGen”, since he is one of the forerunners in sensitization testing, says Prof Carl Borrebaeck, “his knowledge and interest in the field of allergy and replacement of animal testing with new technologies is very important to us. We value his participation in developing the next generation tests.”

About SenzaGen

SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.

SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development.



SenzaGen AB services will offer the most accurate, animal-free *in vitro* testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.

SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.

www.senzagen.com

For more information please contact:

Anki Malmborg Hager, CEO, SenzaGen AB

amh@senzagen.com

+46 768 284822